<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7332875\results\search\disease\results.xml">
  <result pre="to SARS-CoV-2. They play a vital role in RNA transcription," exact="viral" post="replication and new virion formation. This study used virtual"/>
  <result pre="molecular dynamics simulation studies for 50â€‰ns. Zidovudine shows a very" exact="stable" post="interaction with fluctuation starting at 2.4â€‰Ã… on 2â€‰ns and"/>
  <result pre="interaction with fluctuation starting at 2.4â€‰Ã… on 2â€‰ns and remained" exact="stable" post="at 3â€‰Ã… from 13 to 50â€‰ns. Thus, paving the"/>
  <result pre="(Huang etÂ al., 2020). The SARS-CoV-2 is causing the COVID-19" exact="disease" post="with variable mortality in different countries of almost all"/>
  <result pre="World Health Organization (WHO) (Eurosurveillance, 2020). It directly affects the" exact="respiratory" post="tract leading to the Acute Respiratory Distress Syndrome (ARDS)"/>
  <result pre="2020). It directly affects the respiratory tract leading to the" exact="Acute" post="Respiratory Distress Syndrome (ARDS) and death in the want"/>
  <result pre="It directly affects the respiratory tract leading to the Acute" exact="Respiratory" post="Distress Syndrome (ARDS) and death in the want of"/>
  <result pre="affects the respiratory tract leading to the Acute Respiratory Distress" exact="Syndrome" post="(ARDS) and death in the want of oxygen (Chen"/>
  <result pre="drugs with additional mechanisms are required to target the several" exact="viral" post="proteins simultaneously. The nucleocapsid N proteins are present in"/>
  <result pre="complex necessary to produce virion core and RNA synthesis for" exact="viral" post="replication (Cong etÂ al., 2019; McBride etÂ al., 2014)."/>
  <result pre="are potential drug targets thus inhibiting N-proteins will impair the" exact="viral" post="replication machinery (Gordon etÂ al., 2020). Many studies have"/>
  <result pre="binding with RNA domains will lead to the inhibition of" exact="viral" post="replication and subsequent virion formation of SARS-CoV-2. 2. Material"/>
  <result pre="of N protein 6VYO of SARS-CoV-2 was retrieved from the" exact="Protein" post="Data Bank (PDB) (https://www.rcsb.org/) for RBD. The resolution of"/>
  <result pre="downloaded from Asinex and PubChem open chemistry databases. Thus, a" exact="total" post="of 8987 (eight thousands nine hundred and eighty-seven) ligands"/>
  <result pre="Lib-B had 265 FDA approved moieties categorized as drug for" exact="infectious disease" post="that were downloaded from NCBI PubChem (https://pubchem.ncbi.nlm.nih.gov/) (Figure 1)."/>
  <result pre="had 265 FDA approved moieties categorized as drug for infectious" exact="disease" post="that were downloaded from NCBI PubChem (https://pubchem.ncbi.nlm.nih.gov/) (Figure 1)."/>
  <result pre="(PDB ID: 6VYO) with Asinex and PubChem database moieties. 2.2." exact="Protein" post="preparation The Schrodingerâ€™s Protein Preparation Wizard was used for"/>
  <result pre="Asinex and PubChem database moieties. 2.2. Protein preparation The Schrodingerâ€™s" exact="Protein" post="Preparation Wizard was used for the preparation of three-dimensional"/>
  <result pre="the radii of Vander Waalâ€™s scaling factor of 1â€‰Ã… with" exact="partial" post="charge cut-off of 0.25â€‰Ã… using OPLS3e force field and"/>
  <result pre="8722 antiviral drugs and 265 FDA approved drugs used for" exact="infectious diseases" post="were selected for virtual screening and molecular docking study"/>
  <result pre="promoters, tautomers and ionization states at pH 7.0 along with" exact="partial" post="atomic charges using OPLS3e force field A. 2.5. Virtual"/>
  <result pre="selected ligands (8722 antiviral drugs, 265 FDA approved drugs for" exact="infectious" post="diseases) for high throughput virtual screening (HTVS) against a"/>
  <result pre="for their binding free energies by prime MM-GBSA (Molecular Mechanics" exact="Generalized" post="Born Surface Area) module of Schrodinger suite with the"/>
  <result pre="was used to saturate, minimizing the energy and determination of" exact="partial" post="charges (Bowers etÂ al., 2006). The complexes were immersed"/>
  <result pre="individual RMSF figures were generated. 3. Results and discussions 3.1." exact="Protein" post="structure reliability and active site selection Quality and reliability"/>
  <result pre="and Proline) 8 Â Proline 64 Â Glycine 40 Â" exact="Total" post="number of residues 499 100 This shows minimum steric"/>
  <result pre="screening &amp;amp;molecular docking The selection of most probable drug candidates" exact="acquired" post="from virtual screening and molecular docking of Asinex and"/>
  <result pre="Zidovudine 72187 Antiviral drug used for the treatment of human" exact="immunodeficiency" post="virus (HIV) infections Nucleoside reverse transcriptase inhibitor (NRTI) with"/>
  <result pre="drug used for the treatment of human immunodeficiency virus (HIV)" exact="infections" post="Nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human"/>
  <result pre="infections Nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human" exact="Immunodeficiency" post="Virus Type 1 (HIV-1) (https://www.drugbank.ca/drugs/DB00495) 2 Valganciclovir 135413534 Antiviral"/>
  <result pre="reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus" exact="Type 1" post="(HIV-1) (https://www.drugbank.ca/drugs/DB00495) 2 Valganciclovir 135413534 Antiviral drug used for"/>
  <result pre="Valganciclovir 135413534 Antiviral drug used for the treatment of cytomegalovirus" exact="infections" post="Inhibition of viral DNA synthesis by incorporation with viral"/>
  <result pre="drug used for the treatment of cytomegalovirus infections Inhibition of" exact="viral" post="DNA synthesis by incorporation with viral DNA&amp;amp; inhibits viral"/>
  <result pre="cytomegalovirus infections Inhibition of viral DNA synthesis by incorporation with" exact="viral" post="DNA&amp;amp; inhibits viral DNA polymerases (https://www.drugbank.ca/drugs/DB01610) 3 Ribavirin 37542"/>
  <result pre="of viral DNA synthesis by incorporation with viral DNA&amp;amp; inhibits" exact="viral" post="DNA polymerases (https://www.drugbank.ca/drugs/DB01610) 3 Ribavirin 37542 Used for the"/>
  <result pre="polymerases (https://www.drugbank.ca/drugs/DB01610) 3 Ribavirin 37542 Used for the treatment of" exact="chronic" post="Hepatitis C virus (HCV) infection Inhibits of viral RNA"/>
  <result pre="(https://www.drugbank.ca/drugs/DB01610) 3 Ribavirin 37542 Used for the treatment of chronic" exact="Hepatitis" post="C virus (HCV) infection Inhibits of viral RNA and"/>
  <result pre="Used for the treatment of chronic Hepatitis C virus (HCV)" exact="infection" post="Inhibits of viral RNA and protein synthesis by inhibition"/>
  <result pre="treatment of chronic Hepatitis C virus (HCV) infection Inhibits of" exact="viral" post="RNA and protein synthesis by inhibition of the enzyme"/>
  <result pre="30â€&quot;36â€‰ns. However, Figure 6A, B and C show the favorable" exact="residual" post="interactions which remained for more than 30% of the"/>
  <result pre="of proteinâ€&quot;ligand interaction fraction over the course of trajectory. (A-2)" exact="Protein" post="residue interactions with ligand 5817. (B) (B-1) The bar"/>
  <result pre="of proteinâ€&quot;ligand interaction fraction over the course of trajectory. (B-2)" exact="Protein" post="residue interactions with ligand 6799. (C) (C-1) The bar"/>
  <result pre="of proteinâ€&quot;ligand interaction fraction over the course of trajectory. (C-2)" exact="Protein" post="residue interactions with ligand 72187 (Zidovudine). Figure 7. Binding"/>
  <result pre="10â€‰ns and 4.8â€‰Ã… from 28 to 50â€‰ns. This interaction remained" exact="stable" post="and sustained for a longer period. The ligand atom"/>
  <result pre="of Zidovudine with the target protein. It shows a very" exact="stable" post="interactions and minimal fluctuation. Its increase started to 2.4â€‰Ã…"/>
  <result pre="fluctuation. Its increase started to 2.4â€‰Ã… on 2â€‰ns and remained" exact="stable" post="up to 3â€‰Ã… from 13 to 50â€‰ns. Its interactions"/>
  <result pre="and C)) that compound 5817, 6799 and 72187 formed more" exact="stable" post="hydrogen bonds with the residues of binding Site 3"/>
  <result pre="Site 3 of target protein. 4. Conclusion We identified a" exact="total" post="of seven hits in the first step after molecular"/>
  <result pre="three drugs. Out of those, Zidovudine has stronger and more" exact="stable" post="interaction with this protein structure. Therefore, the drugs especially"/>
  <result pre="S83â€&quot;S88. 10.1016/S1359-6446(02)02288-212047885 ChangC.-K., Michael ChenC.-M., ChiangM.-H., HsuY.-I., &amp;amp; HuangT.-H. (2013)." exact="Transient" post="oligomerization of the SARS-CoV N protein â€&quot; Implication for"/>
  <result pre="NingQ. (2020). Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: Retrospective study. BMJ (Clinical Research ed.), 368, m109110.1136/bmj.m1091"/>
  <result pre="1â€&quot;14. 10.1080/07391102.2020.1772885 DineshD. C., ChalupskaD., SilhanJ., VeverkaV., &amp;amp; BouraE. (2020)." exact="Structural" post="basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein."/>
  <result pre="(2020). In-silico approaches to detect inhibitors of the human severe" exact="acute" post="respiratory syndrome coronavirus envelope protein ion channel. Journal of"/>
  <result pre="In-silico approaches to detect inhibitors of the human severe acute" exact="respiratory" post="syndrome coronavirus envelope protein ion channel. Journal of Biomolecular"/>
  <result pre="approaches to detect inhibitors of the human severe acute respiratory" exact="syndrome" post="coronavirus envelope protein ion channel. Journal of Biomolecular Structure"/>
  <result pre="LiuC. L., ChangY. M., ZhaoJ., PerlmanS., &amp;amp; HouM. H. (2014)." exact="Structural" post="basis for the identification of the N-terminal domain of"/>
  <result pre="120â€&quot;127. 10.1016/j.febslet.2012.11.01623178926 Madhavi SastryG., AdzhigireyM., DayT., AnnabhimojuR., &amp;amp; ShermanW. (2013)." exact="Protein" post="and ligand preparation: Parameters, protocols, and influence on virtual"/>
  <result pre="than just the common cold. JAMA â€&quot; Journal of the" exact="American" post="Medical Association, 323(8), 70710.1001/jama.2020.0757 SarmaP., SekharN., PrajapatM., AvtiP., KaurH.,"/>
  <result pre="GuillemotJ.-C., DecrolyE., PeersenO., FerronF., &amp;amp; CanardB. (2020). Remdesivir and SARS-CoV-2:" exact="Structural" post="requirements at both nsp12 RdRp and nsp14 exonuclease active-sites."/>
  <result pre="K., &amp;amp; LalS. K. (2006). The nucleocapsid protein of severe" exact="acute" post="respiratory syndrome-coronavirus inhibits the activity of cyclinâ€&quot;cyclin-dependent kinase complex"/>
  <result pre="&amp;amp; LalS. K. (2006). The nucleocapsid protein of severe acute" exact="respiratory" post="syndrome-coronavirus inhibits the activity of cyclinâ€&quot;cyclin-dependent kinase complex and"/>
  <result pre="F., &amp;amp; TanW. (2020). A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. The New England Journal of Medicine,"/>
  <result pre="of Medicine, 382(8), 727â€&quot;733. 10.1056/NEJMoa200101731978945 Abbreviations CoV coronavirus COVID-19 coronavirus" exact="disease" post="2019 FDA food and drug administration HB hydrogen bond"/>
  <result pre="high throughput virtual screening MD molecular dynamics MERS Middle East" exact="Respiratory" post="Syndrome PDB Protein Data Bank RNA ribonucleic acid SARS"/>
  <result pre="throughput virtual screening MD molecular dynamics MERS Middle East Respiratory" exact="Syndrome" post="PDB Protein Data Bank RNA ribonucleic acid SARS Sudden"/>
  <result pre="screening MD molecular dynamics MERS Middle East Respiratory Syndrome PDB" exact="Protein" post="Data Bank RNA ribonucleic acid SARS Sudden Acute Respiratory"/>
  <result pre="Syndrome PDB Protein Data Bank RNA ribonucleic acid SARS Sudden" exact="Acute" post="Respiratory Syndrome SP standard precision WHO World Health Organization"/>
  <result pre="PDB Protein Data Bank RNA ribonucleic acid SARS Sudden Acute" exact="Respiratory" post="Syndrome SP standard precision WHO World Health Organization XP"/>
  <result pre="Protein Data Bank RNA ribonucleic acid SARS Sudden Acute Respiratory" exact="Syndrome" post="SP standard precision WHO World Health Organization XP extra"/>
 </snippets>
</snippetsTree>
